On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Jul. 19, 2022, Yale scientists announced they had developed a novel Omicron-specific mRNA vaccine that offers superior…
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
On Jun. 23, 2022, BioNTech announced it had reached a milestone in the establishment of scalable mRNA vaccine…
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
On Jun. 15, 2022, Roche announced that the US Food and Drug Administration had issued Emergency Use Authorization…
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
On May 18, 2022, SARS-CoV-2, or at least pieces of it, sticks around longer in some infected individuals…
On May 13, 2022, the Tabula Sapiens Consortium announced it had published a molecular reference atlas for more…
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
On Apr. 11, 2022, CureVac and GSK announced that they had entered into a contract with the German…
On Apr. 9, 2022, BioNTech announced it was granted a pandemic preparedness contract by the Federal Republic of…
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
On Mar. 29, 2022, Moderna announced that it had received approval from the U.S. Food and Drug Administration…
On Mar. 23, 2022, Moderna announced the finalization of a strategic partnership with the Australian Federal Government to…
On Mar. 23, 2022, Moderna announced positive interim data from the Phase 2/3 KidCOVE study of the Moderna…
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…